Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02218125 · ClinicalTrials.gov registry record · Phase 1

A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults

A Phase 1 study of Healthy, sponsored by Crucell Holland.

Completed
Registry status
Phase 1
Development phase
25
Enrollment target
1
Study location

NCT02218125: Completed Phase 1 study of Healthy, sponsored by Crucell Holland.

NCT02218125 is a Phase 1 study of Healthy that has completed, run by Crucell Holland. The registered enrollment target is 25 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02218125, a Phase 1 study of Healthy, has completed, sponsored by Crucell Holland.

COMPLETED
Registry status
Phase 1
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the safety and tolerability of Modified Vaccinia Ankara (MVA) Mosaic vaccine in healthy adult participants.

Conditions Studied

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL MVA Mosaic

Study Locations (1)

Massachusetts

  • - Boston

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2014-09-23
Est. Completion 2015-11-30
Phase Phase 1

Sponsor

Crucell Holland

10 total trials

What the Registry Record Tells You About NCT02218125

The ClinicalTrials.gov registry entry for NCT02218125 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The listed sponsor is Crucell Holland, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02218125 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02218125 about?

NCT02218125 is a clinical study titled "A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults". The purpose of this study is to assess the safety and tolerability of Modified Vaccinia Ankara (MVA) Mosaic vaccine in healthy adult participants.

What is the current status of trial NCT02218125?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2014-09-23. Estimated completion is 2015-11-30.

What conditions does trial NCT02218125 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT02218125?

The interventions under investigation include: Placebo (BIOLOGICAL), MVA Mosaic (BIOLOGICAL).

Who is sponsoring clinical trial NCT02218125?

This trial is sponsored by Crucell Holland, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02218125 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.